Replies to post #115165 on Biotech Values

[mcbio]

I’m not sure this is true. For instance, GILD has a PI in phase-1 but has not yet disclosed any details to investors.

Thanks Dew. I will need to keep closer tabs on that one.

I still have one stock I'm looking to add and I will consider ACHN again post 28-day results for ACH-1625 though I'm more than likely going to wait until after the 12-week data is posted towards the end of the year. I think it's probably going to take more than just positive 12-week results at the end of the year to vault ACHN significantly higher from the current level. I think investors are so infatuated with VRTX and telaprevir that they're likely still not going to give 1625 its due given that it's so far behind telaprevir. I think that view is a bit misguided though and I think a significant deal with a big pharma could change that sentiment. I think that's likely to occur after the 12-week data is announced, assuming it is positive. Hopefully I can avoid two important binary events and still have a potential buying opportunity in ACHN at the end of the year.